New drug cocktail aims to tackle tough lymphoma
NCT ID NCT04855695
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—for people with mantle cell lymphoma that has come back or hasn't been treated yet. The goal is to find the best dose and see how well it works at shrinking tumors. About 72 participants will take part in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib, venetoclax, and obinutuzumab
What this could lead to
If successful, this combination could offer a new treatment option for mantle cell lymphoma, potentially improving remission rates.
What could go wrong
This is an early-phase trial with a small number of participants. The combination may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Contact
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact